Skip to main content
Clinical Trials/ChiCTR2100048793
ChiCTR2100048793RecruitingUnknown

呼出气冷凝液 VOC 联合尿液代谢产物分析呼吸机相关性肺炎患者的预后作用

院级课题科研经费1 site in 1 country200 target enrollmentStarted: January 1, 2022Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Unknown
Status
Recruiting
Sponsor
Enrollment
200
Locations
1
Primary Endpoint
挥发性有机物

Study Overview

Brief Summary

通过 VAP 患者检测呼出气冷凝液 VOC 和尿液中代谢组学中相关指标变化,确定多治疗联合评估 VAP 患者的疾病进展情况,阐明冷凝液 VOC 和尿液中代谢产物在评估 VAP 患者预后的价值。

Study Design

Study Type
Observational

Eligibility Criteria

Ages
18 to 90 (—)
Sex
All

Inclusion Criteria

  • 1.2017.9.1 日至 2021.8.31 入住 ICU,因呼吸功能失代偿或自主呼吸试验失败无法脱机拔管,需要气管插管机械通气的患者;
  • 3.签署知情同意书自愿参加本回顾性研究者。

Exclusion Criteria

  • 患者存在气道出血,气道畸形,吸入性肺烧伤等情况及解剖结构异常。

Arms & Interventions

3 组

Intervention: 3 组

4 组

Intervention: 4 组

1 组

Intervention: 1 组

2 组

Intervention: 2 组

Outcomes

Primary Outcomes

挥发性有机物

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
院级课题科研经费

Study Sites (1)

Loading locations...

Similar Trials